Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma

Cell Reports

Volumn 15, Issue 4, 2016, Pages 857-865

  Giannakis, Marios ^a,b,c   Mu, Xinmeng Jasmine ^a,b,c   Shukla, Sachet A ^a,c   Qian, Zhi Rong ^a   Cohen, Ofir ^a,c   Nishihara, Reiko ^a,d   Bahl, Samira ^c   Cao, Yin ^d,e   Amin Mansour, Ali ^a,c   Yamauchi, Mai ^a   Sukawa, Yasutaka ^f   Stewart, Chip ^c   Rosenberg, Mara ^c   Mima, Kosuke ^a   Inamura, Kentaro ^a   Nosho, Katsuhiko ^g   Nowak, Jonathan A ^b   Lawrence, Michael S ^c   Giovannucci, Edward L ^a,d   Chan, Andrew T ^a,e   Ng, Kimmie ^a,b   Meyerhardt, Jeffrey A ^a,b   Van Allen, Eliezer M ^a,b,c   Getz, Gad ^a,c   Gabriel, Stacey B ^c   Lander, Eric S ^a,c,h   Wu, Catherine J ^a,b,c   Fuchs, Charles S ^a,b   Ogino, Shuji ^a,b,d   Garraway, Levi A ^a,b,c   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f KEIO UNIVERSITY   (Japan)

^g SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN; KRUPPEL LIKE FACTOR 5; TRANSCRIPTION FACTOR CTCF;

ANTIGEN PRESENTATION; ARTICLE; B CELL CLL LYMPHOMA 9 LIKE GENE; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CCCTC BINDING FACTOR GENE; COLORECTAL CANCER; CONTROLLED STUDY; GENE; GENE MUTATION; GENETIC SELECTION; GENOMICS; HLA GENE; HUMAN; HUMAN TISSUE; KRUEPPEL LIKE FACTOR 5 GENE; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MEMORY T LYMPHOCYTE; OVERALL SURVIVAL; POSITIVE SELECTION; PRIORITY JOURNAL; RBM10 GENE; SEQUENCE ANALYSIS; SOMATIC MUTATION; TUMOR ASSOCIATED LEUKOCYTE; WHOLE EXOME SEQUENCING;

EID: 84963553379     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2016.03.075     Document Type: Article

References (32)

1. Angelova M., Charoentong P., Hackl H., Fischer M.L., Snajder R., Krogsdam A.M., Waldner M.J., Bindea G., Mlecnik B., Galon J., Trajanoski Z. Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy. Genome Biol. 2015, 16:64.
2. Brembeck F.H., Wiese M., Zatula N., Grigoryan T., Dai Y., Fritzmann J., Birchmeier W. BCL9-2 promotes early stages of intestinal tumor progression. Gastroenterology 2011, 141:1359-1370. 1370.e1-1370.e3.
3. Brown S.D., Warren R.L., Gibb E.A., Martin S.D., Spinelli J.J., Nelson B.H., Holt R.A. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res. 2014, 24:743-750.
4. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487:330-337. Cancer Genome Atlas Network.
5. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014, 511:543-550. Cancer Genome Atlas Research Network.
6. Chan A.T., Ogino S., Fuchs C.S. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N. Engl. J. Med. 2007, 356:2131-2142.
7. Cibulskis K., Lawrence M.S., Carter S.L., Sivachenko A., Jaffe D., Sougnez C., Gabriel S., Meyerson M., Lander E.S., Getz G. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 2013, 31:213-219.
8. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pagès C., Tosolini M., Camus M., Berger A., Wind P., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964.
9. Garraway L.A., Lander E.S. Lessons from the cancer genome. Cell 2013, 153:17-37.
10. Giannakis M., Hodis E., Jasmine Mu X., Yamauchi M., Rosenbluh J., Cibulskis K., Saksena G., Lawrence M.S., Qian Z.R., Nishihara R., et al. RNF43 is frequently mutated in colorectal and endometrial cancers. Nat. Genet. 2014, 46:1264-1266.
11. Jass J.R., Do K.A., Simms L.A., Iino H., Wynter C., Pillay S.P., Searle J., Radford-Smith G., Young J., Leggett B. Morphology of sporadic colorectal cancer with DNA replication errors. Gut 1998, 42:673-679.
12. Kanehisa M., Goto S., Sato Y., Kawashima M., Furumichi M., Tanabe M. Data, information, knowledge and principle: back to metabolism in KEGG. Nucleic Acids Res. 2014, 42:D199-D205.
13. Katainen R., Dave K., Pitkänen E., Palin K., Kivioja T., Välimäki N., Gylfe A.E., Ristolainen H., Hänninen U.A., Cajuso T., et al. CTCF/cohesin-binding sites are frequently mutated in cancer. Nat. Genet. 2015, 47:818-821.
14. Lawrence M.S., Stojanov P., Mermel C.H., Robinson J.T., Garraway L.A., Golub T.R., Meyerson M., Gabriel S.B., Lander E.S., Getz G. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014, 505:495-501.
15. Le D.T., Uram J.N., Wang H., Bartlett B.R., Kemberling H., Eyring A.D., Skora A.D., Luber B.S., Azad N.S., Laheru D., et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 2015, 372:2509-2520.
16. Liao X., Lochhead P., Nishihara R., Morikawa T., Kuchiba A., Yamauchi M., Imamura Y., Qian Z.R., Baba Y., Shima K., et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N. Engl. J. Med. 2012, 367:1596-1606.
17. Nakaya T., Ogawa S., Manabe I., Tanaka M., Sanada M., Sato T., Taketo M.M., Nakao K., Clevers H., Fukayama M., et al. KLF5 regulates the integrity and oncogenicity of intestinal stem cells. Cancer Res. 2014, 74:2882-2891.
18. Nielsen M., Lundegaard C., Blicher T., Lamberth K., Harndahl M., Justesen S., Røder G., Peters B., Sette A., Lund O., Buus S. NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence. PLoS ONE 2007, 2:e796.
19. Nishihara R., Wu K., Lochhead P., Morikawa T., Liao X., Qian Z.R., Inamura K., Kim S.A., Kuchiba A., Yamauchi M., et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N. Engl. J. Med. 2013, 369:1095-1105.
20. Nosho K., Baba Y., Tanaka N., Shima K., Hayashi M., Meyerhardt J.A., Giovannucci E., Dranoff G., Fuchs C.S., Ogino S. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J. Pathol. 2010, 222:350-366.
21. Ogino S., Nosho K., Irahara N., Meyerhardt J.A., Baba Y., Shima K., Glickman J.N., Ferrone C.R., Mino-Kenudson M., Tanaka N., et al. Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin. Cancer Res. 2009, 15:6412-6420.
22. Ogino S., Galon J., Fuchs C.S., Dranoff G. Cancer immunology-analysis of host and tumor factors for personalized medicine. Nat. Rev. Clin. Oncol. 2011, 8:711-719.
23. Pagès F., Berger A., Camus M., Sanchez-Cabo F., Costes A., Molidor R., Mlecnik B., Kirilovsky A., Nilsson M., Damotte D., et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med. 2005, 353:2654-2666.
24. Rajasagi M., Shukla S.A., Fritsch E.F., Keskin D.B., DeLuca D., Carmona E., Zhang W., Sougnez C., Cibulskis K., Sidney J., et al. Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood 2014, 124:453-462.
25. Saeterdal I., Bjørheim J., Lislerud K., Gjertsen M.K., Bukholm I.K., Olsen O.C., Nesland J.M., Eriksen J.A., Møller M., Lindblom A., Gaudernack G. Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. Proc. Natl. Acad. Sci. USA 2001, 98:13255-13260.
26. Saunders C.T., Wong W.S., Swamy S., Becq J., Murray L.J., Cheetham R.K. Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. Bioinformatics 2012, 28:1811-1817.
27. Schumacher T.N., Schreiber R.D. Neoantigens in cancer immunotherapy. Science 2015, 348:69-74.
28. Schwitalle Y., Kloor M., Eiermann S., Linnebacher M., Kienle P., Knaebel H.P., Tariverdian M., Benner A., von Knebel Doeberitz M. Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology 2008, 134:988-997.
29. Seshagiri S., Stawiski E.W., Durinck S., Modrusan Z., Storm E.E., Conboy C.B., Chaudhuri S., Guan Y., Janakiraman V., Jaiswal B.S., et al. Recurrent R-spondin fusions in colon cancer. Nature 2012, 488:660-664.
30. Shukla S.A., Rooney M.S., Rajasagi M., Tiao G., Dixon P.M., Lawrence M.S., Stevens J., Lane W.J., Dellagatta J.L., Steelman S., et al. Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat. Biotechnol. 2015, 33:1152-1158.
31. Van Allen E.M., Wagle N., Stojanov P., Perrin D.L., Cibulskis K., Marlow S., Jane-Valbuena J., Friedrich D.C., Kryukov G., Carter S.L., et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat. Med. 2014, 20:682-688.
32. Witkiewicz A.K., McMillan E.A., Balaji U., Baek G., Lin W.C., Mansour J., Mollaee M., Wagner K.U., Koduru P., Yopp A., et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat. Commun. 2015, 6:6744.